Last Price$94.32NASDAQ Closing Price as of 4:00PM ET 8/10/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-2.61(2.69%)
Bid (Size)$93.01 (1)
Ask (Size)$94.32 (20)
Day Low / High$92.94 - 97.16
Volume1.2 M

View Biotechnology IndustryPeer Comparison as of 08/10/2020


Incyte Corp ( NASDAQ )

Price: $94.32
Change: -2.61 (2.69%)
Volume: 1.2 M
4:00PM ET 8/10/2020

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $118.25
Change: -0.42 (0.35%)
Volume: 785.3 K
4:00PM ET 8/10/2020

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $101.91
Change: -1.37 (1.33%)
Volume: 1.8 M
4:00PM ET 8/10/2020

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $138.57
Change: -4.96 (3.46%)
Volume: 533.5 K
4:00PM ET 8/10/2020

Seattle Genetics Inc ( NASDAQ )

Price: $157.70
Change: -2.75 (1.71%)
Volume: 913.8 K
4:00PM ET 8/10/2020

Read more news Recent News

2020 and 2021 Estimates for Incyte Bumped Up but Q3 Earnings Number Falls
7:00AM ET 8/07/2020 MT Newswires

Incyte Corp's (NASDAQ:INCY, Recent Price: 97.25) forecasted earnings estimates for Q3 ending September 30, 2020, and the expectations for 2020 and 2021...

--Analyst Actions: Credit Suisse Cuts PT on Incyte to $97 From $100; Maintains Neutral
1:05PM ET 8/06/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

2020 Estimate for Incyte Increased but Q3, and 2021 Numbers Scaled Down
5:00AM ET 8/06/2020 MT Newswires

Forecasted earnings estimates for Incyte Corp's (NASDAQ:INCY, Recent Price: 97.62) Q3 ending September 30, 2020, and the full year expectations for 2020...

Analyst Actions: RBC Capital Lifts Incyte's Price Target to $96 From $92, Maintains Sector Perform Rating
8:08AM ET 8/05/2020 MT Newswires

Incyte's (INCY) average rating among analysts is a buy, with an average price target of $102. (MT Newswires covers equity, commodity and economic research...

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Number of Employees1,367
Recent SEC Filing08/04/20208-K
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$96.76
Previous Close$96.93
52 Week Range$62.48 - 110.37
Market Capitalization$20.6 B
Shares Outstanding218.7 M
SectorHealth Technology
Next Earnings Announcement11/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.93
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin-8.00%
Return on Equity-8.22%

Analyst Ratings as of 07/13/2020

Consensus RecommendationConsensus Icon
Powered by Factset